In order to ensure 2023 billing, testing must be activated before the end of the year, or within 30 days of proband sample collection (if sample was collected in 2023). For Exome, Genome, or Xpanded testing, if you do not expect parental samples to be received in time for testing to be activated with 2023 billing, please contact us at support@genedx.com to determine how to proceed.

GeneDx logo
Icon for AccountAccount
Icon for ContactContact

Disease should be rare. Diagnosis shouldn’t.

That’s the future we’re building at GeneDx.

Comprehensive genomic insights. Precision medicine. Improved outcomes.

We deliver personalized and actionable health insights that inform diagnosis, direct treatment, and improve drug discovery

Are you a healthcare provider?

Discover how genetic testing could benefit your practice and your patients.

Learn more

Are you a patient or caregiver?

Find answers to your genetic testing questions.

Learn more

Help your patients reach a genetic diagnosis faster with genome and exome testing

We’re moving exome and genome from specialized tests to the standard of care, improving patients’ lives by building a future where we can sequence DNA once and analyze the results for a lifetime.

Graphic of ~2-3x

Whole exome sequencing (WES) can deliver ~2-3x the diagnostic yield of chromosomal microarray (CMA) and multigene panels1-4

Discover exome sequencing

Graphic of 1 in 4

1 in 4 babies in the NICU is likely to have a genetic condition that could be diagnosed with rapid whole genome sequencing5

Discover genome sequencing

Graphic for Patients

More actionable results.
More effective treatment plans.

We leverage our extensive database and proprietary interpretation services to analyze genetic information, enabling a greater chance of a genetic diagnosis. These comprehensive and personalized insights can help inform healthcare decisions and connect patients with crucial resources.

Explore our offerings

With comprehensive care from start to finish, we offer more than just a test result

  • We’re a leader in genomics. We’ve interpreted and delivered over 500,000 clinical exome and genome tests allowing us to offer premier exome sequencing expertise for pediatric conditions and rare and ultra-rare genetic diseases, while enabling precision medicine as the standard of care.
  • We deliver better health insights. Centrellis®, our proprietary health intelligence platform, integrates digital tools with artificial intelligence to ingest and synthesize clinical and genomic data.
  • We back our science with support. Our dedicated team of genetic counselors provides peer-to-peer support as well as pre-and post-test counseling services.
Learn more about GeneDx

In the news

November 20, 2023

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GeneDx today announced that, effective as of November 17, 2023, the compensation committee of GeneDx’s board of directors granted newly hired employees 10,000 restricted stock units (“RSUs”) as inducements material to each employee entering into employment with GeneDx.

Read more

October 30, 2023

GeneDx Reports Third Quarter 2023 Financial Results and Business Highlights

GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today reported its financial results for the third quarter of 2023.

Read more

October 9, 2023

GeneDx to Report Third Quarter 2023 Financial Results on Monday, October 30, 2023

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financial results for the third quarter of 2023 after the market closes on Monday, October 30, 2023.

Read more